Market Overview

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN), as the biotech's initial candidates will enter the clinic over the next year.

The Analyst

Robert Driscoll of Wedbush initiated coverage on Apline with an Outperform rating and $13 price target.

The Thesis

Alpine’s “directed evolution” approach to multifunctional protein-based therapeutics could modulate immune synapse better than conventional immunotherapeutics for treatment of cancer and autoimmune or inflammatory diseases, Driscoll said in a note. (See the analyst's track record here.) 

The company's variable immunoglobin domain platform uses directed evolution to create novel therapeutics and could have a broad utility across therapeutic modalities, the analyst said.

Alpine's ALPN-101 is expected to enter the clinic in the fourth quarter, Driscoll said. 

“ALPN-101 has demonstrated compelling preclinical activity in multiple models of inflammation and autoimmune disease." 

Another key asset is the ALPN-202 immuno-oncology program, which could prove to be a strong competitor, the analyst said. 

“We see the targeting of multiple pathways with a single molecule as providing significant advantages over other I-O combination approaches in development, including selectivity, convenience and cost.”

Price Action

Alpine shares were rallying nearly 10 percent to $9.69 at the time of publication Friday afternoon. 

Related Links:

Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades

Zoetis To Buy Abaxis In $2B Deal

Latest Ratings for ALPN

Sep 2018Initiates Coverage OnOverweight
Jun 2018Initiates Coverage OnOutperform
May 2018Initiates Coverage OnOutperform

View More Analyst Ratings for ALPN
View the Latest Analyst Ratings

Posted-In: Robert Driscoll WedbushAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (ALPN)

View Comments and Join the Discussion!

Latest Ratings

TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at